1.25 mg semaglutide

1.25 mg semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Our wave of revolutionary weight

Name: 1.25 mg semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Our wave of revolutionary weight
Brand: actil.am
SKU: 64680912078
Price: 28.98 USD
Availability: InStock
Rating: 4.7776000000000005 (10 reviews)

SKU: 64680912078

4.8

USD28.98 USD75.98

Pay in 4 interest-free payments of $7.25 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 19 - Aug 24

Description

For researchers exploring the DAC-modified variant, we also offer CJC-1295 DAC

Nothing seems to work externally

It works by simultaneously activating three receptors glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors producing significant reductions in body weight and improvements in metabolic markers